Sky Labs' CART BP pro at the Heart of New Research on Sleep Apnea and Nocturnal Hypertension
SEOUL, South Korea, April 28, 2025 /PRNewswire/ -- Sky Labs, a health-tech startup based in South Korea and the developer of CART BP pro—a ring-type, cuffless device for 24-hour blood pressure monitoring—announced that a research presentation by Professor Jin Oh Na introduced the application of CART BP pro in exploring the relationship between sleep and cardiovascular patterns, offering an opportunity to gain deeper insights into cardiovascular risks during sleep.
This study represents a meaningful step forward in cardiovascular research. Until now, studying the connection between sleep-disordered breathing and hypertension has been limited due to constraints in traditional measurement tools. With CART BP pro, researchers can gather uninterrupted blood pressure data, offering an opportunity to better understand cardiovascular patterns during sleep.
Professor Jin Oh Na of Korea University Guro Hospital's Cardiovascular Center presented a research plan under the theme 'Sleep and Cardiovascular Health: Why It Matters' at the 2025 Annual Spring Scientific Conference of the Korean Society of Cardiology. His upcoming research will explore the correlation between sleep apnea and cardiovascular risks using CART BP pro to measure blood pressure noninvasively during sleep.
'Obstructive sleep apnea is a condition that affects cardiovascular health but is frequently underdiagnosed. In Korea, about 85% of OSA patients remain undiagnosed, often dismissed as simple snoring,' said Professor Na. 'We are planning a study to measure nighttime blood pressure every five minutes using CART BP pro, with the aim of developing a model that may help identify patients at risk and support long-term assessment.'
CART BP pro offers several advantages for both clinical practice and research:
Professor Na pointed out that while polysomnography (PSG) is the current gold standard for diagnosing sleep apnea, it does not allow for precise blood pressure monitoring during sleep. He explained that cuff-based devices may disturb sleep due to pressure inflation and are not suitable for high-frequency nocturnal measurements. By using CART BP pro, researchers expect to collect more consistent, real-world data without interfering with sleep.
The 2025 Annual Spring Scientific Conference held from April 17 to 19 in Busan, Korea, was jointly hosted with the 29th Asian Pacific Society of Cardiology Congress and attended by leading cardiology experts from across the region.
Currently available at more than 1,300 hospitals and clinics throughout South Korea, CART BP pro has received regulatory approval from the Ministry of Food and Drug Safety (MFDS) and is eligible for national health insurance reimbursement, making it more accessible to a broader range of patients.
About Sky Labs
Founded in September 2015, Sky Labs is a leading healthcare startup that has developed CART (Cardio Tracker), a ring-shaped medical device designed for disease monitoring using heart signals collected through optical sensors. Following this, the company developed CART BP, a cuffless, ring-shaped device that enables 24-hour blood pressure monitoring, providing valuable treatment information and making a groundbreaking contribution to improving the quality of life for hypertension patients. Sky Labs has signed an exclusive domestic distribution agreement for CART BP pro with South Korea's Daewoong Pharmaceutical and is preparing for nationwide sales to hospitals, clinics, and general consumers.
Media Inquiries
Edelman Korea [email protected]
View original content to download multimedia: https://www.prnewswire.com/news-releases/sky-labs-cart-bp-pro-at-the-heart-of-new-research-on-sleep-apnea-and-nocturnal-hypertension-302439240.html
SOURCE Sky Labs
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
CureLab Veterinary's ElenaVet™ Gene Therapy Delivers 90% Success in Pet-Dog Osteoarthritis Study
Frontiers in Veterinary Science paper reports rapid, significant pain relief with weekly p62-plasmid injections and no significant side-effects BOSTON, June 13, 2025 /PRNewswire/ -- CureLab Veterinary Inc., a pioneer in developing innovative veterinary therapeutics to combat cancer and inflammatory diseases in pets, announced publication of a peer-reviewed pilot study demonstrating that ElenaVet™, the company's investigational p62-plasmid gene therapy, markedly reduced chronic osteoarthritis (OA) pain in companion dogs while exhibiting an excellent safety profile. The article, titled "Efficacy of p62-expressing plasmid in treatment of canine osteoarthritis pain: a pilot study," appears in Frontiers in Veterinary Science (DOI 10.3389/fvets.2025.1519881). Key findings 17 client-owned dogs with radiographically confirmed OA received 1 mg intramuscular ElenaVet™ once a week for 10 weeks. Pain Severity Score (PSS) fell from 5.25 → 3.25 and Pain Interference Score (PIS) from 7.0 → 3.27 on the Canine Brief Pain Inventory (CBPI). 90% of dogs met the study's pre-defined "treatment success" criteria (≥1-point PSS drop and ≥2-point PIS drop). Quality-of-life ratings of "good/excellent" rose from 1 to 12 dogs. First owner-noticed improvements occurred within 2–4 weeks; scores plateaued by week 6. No significant adverse events—no vomiting, diarrhea, seizures, or lab abnormalities—were reported during treatment. Executive & scientific commentary"ElenaVet™ has now shown—in a rigorous, peer-reviewed setting—that a weekly gene-based therapy can deliver meaningful, durable pain relief without the organ-toxicity risks of long-term NSAID use," said Robert Devlin, general manager of CureLab Veterinary. "These results put us on a clear path toward larger, controlled trials and eventual U.S. approval." "The p62 plasmid dampens multiple inflammatory pathways simultaneously," added Vladimir Gabai, PhD, chief science officer and lead author of the study. "Because we encode p62 in a simple plasmid, we can administer a low-dose injection that teaches muscle cells to make the dog's own anti-inflammatory agent—no complex biologic manufacturing or cold chain required." Addressing a widespread unmet needOsteoarthritis affects an estimated one in five adult dogs; chronic use of standard NSAIDs can raise blood pressure, cause gastric ulcers and, in some cases, damage kidneys or liver. ElenaVet™ aims to offer a safer, compliance-friendly alternative—potentially as monthly or "as-needed" injections, once dose-frequency optimization studies are complete. Next stepsCureLab Veterinary has initiated discussions with the USDA Center for Veterinary Biologics (CVB) to finalize pivotal study protocols assessing dose range, durability of effect and long-term safety. With adequate funding, the company anticipates submitting a licensing application within 2–3 years. About ElenaVet™ElenaVet™ is a circular DNA plasmid encoding the SQSTM1/p62 protein, delivered via intramuscular injection. The therapy is designed to up-regulate the body's own anti-inflammatory mediators, providing multimodal relief from chronic inflammatory conditions such as osteoarthritis. About CureLab Veterinary Veterinary Inc. is a pioneering biopharmaceutical company dedicated to developing innovative cancer treatments for pets. The company's mission is to help pets live longer, healthier, and happier lives by providing them with access to the most advanced therapies available. CureLab Veterinary is committed to advancing the field of veterinary oncology through research, development, and collaboration with leading academic institutions and industry partners. The company's intellectual property portfolio, developed over the last decade, includes patents granted in more than 25 countries. To learn more, visit Investigational status / safe-harbor statementElenaVet™ is an investigational therapy not yet approved for commercial use; safety and efficacy have not been established by U.S. regulatory authorities. This press release contains forward-looking statements subject to risks and uncertainties. Media contactTim Cox | ZingPR for CureLab Veterinary | tim@ View original content to download multimedia: SOURCE CureLab Veterinary Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Billions in Deals Reshaping the Cell and Gene Therapy Industry, reports Kalorama Information
ARLINGTON, Va., June 13, 2025 /PRNewswire/ -- Kalorama Information, a leading publisher of life sciences market research, has released the highly anticipated third edition of its landmark report, Cell and Gene Therapy Market Deals: Investments, M&As, and Partnerships, 2021–2025. This comprehensive analysis offers an in-depth look at the financial ecosystem fueling the explosive growth of the cell and gene therapy (CGT) industry — a market defined by breakthrough innovation, global competition, and evolving funding landscapes. The report is released in two installments, with the first part available now, covering deals through Q4 2024. The second installment, included with purchase, will be released in Fall 2025 and cover activity through Q3 2025. "Many categories of deals, such as collaborations, distribution/co-marketing, and manufacturing/supply chain, have shown a long-term pattern of growth," said Justin Saeks, senior market analyst at Kalorama Information. "And there's reason for optimism regarding continued investments. Cell and gene therapy-related companies have continued to receive huge amounts of investment." Key Insights from the Report: Over 2,000 CGT-related deals analyzed, with quarterly trends tracked from Q1 2021 to Q4 2024 Despite a tighter funding environment, 2024 investment reached an estimated $39 billion, with a sharp Q4 uptick Top dealmakers include Astellas, Bristol Myers Squibb, Ginkgo Bioworks, Charles River, and Eli Lilly Deal types covered: VC/PE, IPO/SPAC, licensing, tech transfer, acquisitions, supply chain partnerships, and more Global perspective includes detailed breakdowns by region — North America, Europe, and APAC Why This Matters Now The CGT market is maturing fast, with fluctuating investment trends, growing deal diversity, and strategic partnerships becoming essential to survival. In 2023 and 2024, firms faced a contraction in available capital — from $73 billion in 2021 down to $35 billion in 2023 — yet collaborative and manufacturing partnerships have been on the rise. This suggests that dealmaking is evolving, not disappearing. Who Should Purchase and Read This Report This report is essential for: Biotech and pharma execs seeking M&A or licensing opportunities VC/PE investors tracking funding cycles and active biotech targets Strategic planners and BD professionals looking to benchmark activity Consultants, CROs, and CMOs aligning services with market needs Regulatory and policy advisors assessing funding shifts and regional dynamics Strategic Use Cases Identify high-activity players and ideal partners for collaboration or acquisition Benchmark funding rounds and valuations for startups or expanding companies Inform R&D focus by tracking which technologies (e.g., CRISPR, AAV) are attracting deals Support global expansion using regional deal patterns and emerging market trends Strengthen regulatory preparedness by understanding the impact of policy shifts on financing Companion Report Available This report pairs with Kalorama's Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 2024–2030 (4th Edition) — offering disease-area breakdowns of the CGT landscape in oncology, neurology, musculoskeletal, and beyond. Get the Report Download or purchase the report here:Cell and Gene Therapy Market Deals: Investments, M&As, and Partnerships, 2021–2025 (3rd Edition) Explore the companion report:Cell and Gene Therapy Market Dynamics by Disease Type, 2024–2030 (4th Edition) About Kalorama InformationKalorama Information, part of Science and Medicine Group, is a trusted source of market research in the life sciences. With a focus on in vitro diagnostics, biotechnology, and medical devices, Kalorama reports are used by top healthcare companies, government agencies, and investment firms worldwide. For purchase or custom consultation, contact:Sheri DavieKalorama Information Sales For media inquiries please contact:Alisa AlvichMarketing View original content to download multimedia: SOURCE Kalorama Information Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Datalogic and B. Braun enable safer oncology treatment with Memor™ 17 Healthcare Certification for OncoSafety Remote Control®
BOLOGNA, Italy, June 13, 2025 /PRNewswire/ -- Datalogic, a global leader in the automatic data capture and factory automation markets, is proud to announce the certification of the Memor 17 Healthcare mobile computer with OncoSafety Remote Control®, the advanced oncology workflow solution developed by B. Braun, a global leader in smart infusion therapy and healthcare technology. This integration combines Datalogic's most advanced healthcare-grade mobile computer with B. Braun's OncoSafety Remote Control®, enabling unmatched traceability, medication accuracy, and compliance in oncology treatment. Together, these technologies deliver a safer, more efficient experience for healthcare professionals and patients alike. Designed for front-line healthcare, the Memor 17 Healthcare features 5G connectivity, Wi-Fi 6E, and an ultra-rugged, disinfectant-ready design. The integrated Halogen™ 2121DL scan engine ensures fast and accurate barcode capture – even on damaged or poorly printed labels – while Datalogic's signature Green Spot technology provides silent scan confirmation, ideal for quiet zones such as neonatal wards or intensive care units. The certification with OncoSafety Remote Control® extends the capabilities of the Memor 17 Healthcare across oncology workflows – from bedside medication administration to remote patient visits – ensuring the highest standards of patient safety, data access, and workflow efficiency. The Memor 17 Healthcare also supports programmable emergency alerts and custom gestures, allowing clinical staff to trigger safety protocols instantly. With long-term Android™ support (version 18 and beyond), AI-powered software tools from the Datalogic Mobility Suite, and a slim, ergonomic form factor, this device is ready to meet the evolving needs of healthcare environments. "The Memor 17 Healthcare sets a new benchmark for patient care and safety in oncology," said Rosario Casillo, Data Capture Product and Solutions Executive VP at Datalogic. "Its certification with B. Braun's OncoSafety Remote Control® enables seamless verification of patient-treatment matching with their advanced solution, ensuring healthcare professionals can rely on a connected, secure, and highly functional device to deliver critical care wherever it's needed." "Our mission at B. Braun is to protect and improve the health of people around the world. We are pleased to collaborate with Datalogic to equip caregivers with the technology needed to make well-informed decisions and reduce medication errors," added Thore Heinemann, Senior Digital Solution Manager at B. Braun. Datalogic GroupA global technology leader in the automatic data capture and industrial automation markets since 1972, specializes in the design and production of barcode readers, mobile computers, sensors for detection, measurement and safety, machine vision and laser marking systems. These products and solutions enhance efficiency and quality across the entire value chain, in industries such as retail, manufacturing, transportation and logistics, and healthcare. Trusted by major global players in its four target sectors, Datalogic is recognized for its customer focus and commitment to quality, upheld by the Group for over 50 years. Today, Datalogic Group, headquartered in Bologna (Italy), employs approximately 2,700 staff worldwide, distributed in 27 countries, with 10 manufacturing and repair facilities in the U.S.A., Hungary, Slovakia, Italy, China, and Vietnam, 10 Research & Development centers and 3 DL Labs in Italy, U.S.A., Vietnam, and Czech Republic. In 2024, Datalogic Group recorded sales of € 493.8 million and invested € 65.9 million in R&D. Datalogic S.p.A. has been listed in the Euronext STAR Milan segment of the Italian Stock Exchange since 2001 as Visit Datalogic and the Datalogic logo are registered trademarks of Datalogic S.p.A. in many countries, including the U.S.A. and the E.U. Other trademarks belong to their respective owners. B. Braun B. Braun is one of the world's leading providers and manufacturers of healthcare solutions developing innovative products and services in smart infusion therapy, anesthesia, intensive care, and oncology. Through partnerships and digital technologies like OncoSafety Remote Control®, B. Braun supports safer, more effective clinical outcomes. View original content: SOURCE Datalogic Sign in to access your portfolio
